, in its filing to the exchanges, informed that the US Food and Drug Administration (USFDA) has classified the company’s Formulations Srikakulam Plant (SEZ) Unit I, Andhra Pradesh as Voluntary Action Initiated (VAI).
In January 2019, USFDA had completed the inspection of the said plant and issued a Form 483 with four observations, the company said in a press note to the exchanges on Friday.
On Friday, financial markets in India were shut on account of Good Friday holiday.
Dr Reddys Laboratories Ltd's share price ended at Rs2,796.50 on Thursday, down by Rs4.4 or 0.16%, from its previous close of Rs2,800.90 on the BSE.
The scrip opened at Rs2,796.50 and touched a high and low of Rs2,796.50 and Rs2,796.50, respectively. A total of, 1,346 (NSE+BSE) shares have traded on the counter. The current market cap of the company is Rs46,513.41cr.